reason report
swimmer need time trial bound impact filgotinib
bottom line potenti delay manta creat uncertainti
model impact find addit manta-ray narrow
bound uncertainti remain outperform lower month
pt per share increas confid
bound uncertainti associ file delay
testicular toxic signal manta sensit pt rang
model profil blemish launch delay use asset-profil
model see understand likelihood delay toxic
signal use comp analysi map speed patient accrual
look histor approv medicin also burden prior
anim testicular toxic see integr data use
modal analysi probabl weight arriv new pt
learn launch delay chang price target
addit manta-ray minim impact like scenario
project month delay manta/manta-ray complet lower
price target per glpg share weight
scenario outcom associ probabl manta/manta-ray
give per share weight price base similar trial
filgotinib expect manta/manta-ray reveal tox signal
likelihood mild likelihood moder likelihood
signal appear believ fda still approv filgotinib base
histor preced set drug similar profil blemish asset
profil weigh price target pend manta/
manta-ray show price target respons
month delay comparison manta trial scenario
start manta-ray acceler launch timelin averag
month ad close npv estim cost
take addit new trial acceler patient recruit
data collect rule testicular toxic strateg sound
translat increment npv base month
time save glpg assist manta-ray increas oper
bandwidth open door european investig excit
prescrib filgotinib discount testicular toxic unlik
base known data date rule imposs see
hope brief analysi give confid
uncertainti associ manta bound glpg
remain sound invest reiter outperform rate
sotp wacc-calcul
discount rate termin growth
rate discount cash flow valu
asset dcf valu
adjust asset specif probabl
year price history/av daili volume mil glpg
compani inform svb leerink llc research
rev mm
pleas refer page import disclosur price chart analyst certif
filgotinib superior safeti profil versu jaki make potenti best-in-class jaki
opportun compet anti-tnf agent rheumatoid arthriti ra inflammatori
bowel diseas ibd believ glpg potenti best-in-car drug
potenti becom standard care ipf treatment limit effect treatment
ipf carri blockbust potenti project market launch view
gain approv treat osteoarthr oa highli unlik given histori clinic effort
ignor massiv opportun gain regulatori approv
expect glpg proprietari discoveri platform continu produc uniqu profil drug
keep door open partnership opportun
pt determin use probabl weight scenario analysi individu scenario
valu determin sum part valuat appli wacc calcul
discount rate termin growth rate revenu cash flow project
revenu asset adjust independ twice probabl regulatori approv
asset specif commerci profil
commerci probabl distribut determin base revenu weight distribut
independ commerci scenario project drug candid filgotinib
compris major valuat galapago held cash cash equival
end forma cash appli valuat
risk valuat includ follow
product risk one clinic trial filgotinib may fail meet
primari endpoint necessit deeper decis continu develop particular
indic addit safeti issu occur within one trial filgotinib may read
neg across entir filgotinib franchis
collabor risk multipl product within glpg pipelin includ filgotinib
develop market away glpg control give glpg limit
abil address situat issu surround success drug
regulatori risk fda previous indic belief drug combin
like futur ipf treatment mind glpg pursu pivot trial investig
combin standard care believ creat safer path
approv nonetheless open door potenti competitor pursu path approv
monotherapi significantli disrupt expect market competit
financ risk glpg current revenu produc product market though well
capit near term neg outcom asset franchis may significantli
impact abil rais fund futur
fda discuss decid fate manta/manta-ray ahead nda file
filgotinib posit result phase finch trial filgotinib rheumatoid arthriti
ra hand glpg collabor partner mp meet fda within
next month discuss pathway forward filgotinib focu fda request
testicular toxic studi complet prior nda file phase manta trial
filgotinib patient ulcer coliti uc initi juli determin effect
filgotinib testicular function howev slow enrol led multipl measur acceler
patient enrol includ expand inclus criteria includ crohn diseas cd
patient initi phase manta-ray studi april extend analysi
patient rheumat diseas reach price target
assumpt nda filgotinib would file time project market launch
howev believ fda unlik revers prior request due
avail treatment ra place high threshold drug seek approv
indic potenti delay creat risk price target glpg
compound possibl trial may detect testicular toxic signal
unknown impact manta/manta-ray price glpg unclear
valuat glpg impact manta/manta-ray like scenario
fda remain firm request trial complet ahead nda file filgotinib
uncertainti aris lack transpar surround enrol rate current
enrol statu trial complic valuat risk possibl
testicular toxic signal could appear final readout manta/manta-ray need
understand impact trial price target
comp analysi scenario analysi two-step approach understand impact
manta/manta-ray understand degre launch delay testicular
toxic signal would impact price target took two-step approach perform comp
analysi scenario analysi comp analysi use estim current enrol
statu manta/manta-ray project time rang primari complet trial
market launch filgotinib base analysi develop probabl distribut
long delay caus manta/manta-ray addit use histor
data approv drug note testicular toxic signal product label basi
estim likelihood manta/manta-ray identifi toxic signal scenario
analysi determin price target distribut base five scenario regard delay
market launch filgotinib versu three scenario regard detect testicular toxic
manta/manta-ray scenario analysi overlaid probabl distribut
determin comp analysi identifi like price target rang calcul
probabl weight averag price across scenario
comp analysi indic year delay market launch caus manta/manta-
ray first step analysi perform comp analysi estim current
enrol statu manta determin potenti enrol rate manta manta-
ray potenti enrol rate determin use histor archiv compar clinic
trial list clinicaltri gov map trial site activ durat activ recruit
versu number patient enrol trial
manta manta-ray design enrol patient activ trial site
manta trial site plan activ manta-ray manta select
patient phase trial upadacitinib crohn diseas patient
phase trial mirikizumab ulcer coliti compar trial
manta-ray use patient phase trial filgotinib ra
patient phase trial upadacitinib ra compar trial
compar trial appli enrol rate display tabl assumpt
use model manta manta-ray map path market launch summar
tabl assumpt use comp analysi manta manta-ray
approach allow us creat upper lower band model high low patient
enrol rate trial expect manta continu activ new trial site
project linear growth total enrol patient move forward sinc manta-ray newli
initi model averag trial site activ per month result exponenti
growth total patient enrol trial manta manta-ray combin
final readout combin total project enrol trial determin
cumul patient enrol project total patient enrol project
enrol complet date display figur
estim manta manta-ray combin enrol patient
date estim enrol complet decemb april base
date rang ad week reach primari endpoint plu addit
month clean analyz present data estim top-lin readout
assumpt resourc heavili deploy expedit process
estim addit month need prepar file nda date
rang also assum prioriti review voucher use
acceler review process lead project approv market launch
date rang indic market launch filgotinib delay
year rel initi project market launch project timelin key date
launch delay summar tabl
testicular toxic low threshold clear reason perform manta manta-
ray appear partial revers reduc sperm concentr rat dog
given slightli higher equival dose mg dose use manta manta-ray
sperm concentr reduc anim model given mg equival dose male ra
patient given either mg mg phase trial show stabl
plasma testosteron concentr within normal rang nmol/l
figur testosteron along along follicl stimul hormon fsh one two
hormon regul spermatogenesi testosteron concentr fulli correl
sperm concentr highli predict leydig cell function significantli impact
sertoli cell activ requir normal spermatogenesi
tabl summari key date launch delay filgotinib base comp
despit posit patient data shown far concern testicular toxic remain uncertain
true probabl signal appear lack certainti skew patient
demograph enrol trial averag ra patient year old ra also
three time common femal male evid ra may
influenc male fertil male patient develop anti-sperm antibodi
statist make us question suitabl ad manta-ray trial contrast averag
age diagnosi year old uc patient year old cd patient neither diseas
link male fertil issu except certain treatment-rel occurr
figur plasma testosteron concentr male patient darwin
fda histori approv allow drug remain market face
evid testicular signal see certain therapi hormon therapi
chemotherapi known expect impact fertil allow due
high unmet medic need address drug use treat inflammatori
diseas prednison methotrex remain heavili prescrib despit scientif
public show effect sperm concentr motil anoth categori drug
includ colchicin demonstr testicular toxic anim translat
human patient base histor preced expect fda lenient decis
mild moder toxic signal appear regardless testicular toxic signal may still
influenc use filgotinib approv
order determin probabl distribut manta/manta-ray readout analyz
market drug previous identifi show testicular toxic either
preclin clinic real world set publish data human avail
drug seven drug publish data human anim studi three
seven drug colchicin dexamethason mercaptopurin find evid testicular
toxic human two seven drug hormon treatment support evid
testicular toxic human two seven drug conflict data human
thu give probabl drug definit data testicular toxic signal
detect manta/manta-ray remain percent apport mild
signal moder signal note probabl signific testicular toxic
signal appear result regulatori failur filgotinib incorpor appli probabl
regulatori success current set filgotinib ra filgotinib
scenario analysi indic price target rang per share glpg
sinc scenario specif defin impact valuat model creat
five scenario begin delay market launch increas year interv
two-year delay interv fit model independ assumpt
tabl asset profil distribut three potenti top-line outcom
similarli appli three potenti scenario relat top-lin result manta/manta-
ray specif impact market profil filgotinib valuat approach model asset
valu probabl distribut across four market scenario breakthrough meaning
increment undifferenti impact potenti testicular toxic signal
incorpor model shift asset profil distribut across scenario tabl
review asset profil valuat approach see deep dive report glpg
scenario analysi reveal price rang per share tabl
price target determin independ probabl distribut scenario
occur initi price target per share yellow made assumpt
filgotinib would launch littl toxic signal
impact price target base manta/manta-ray
bounti effect treatment avail use believ current treatment landscap
ra motiv fda revers decis allow nda file filgotinib prior
complet manta/manta-ray view likelihood fda accept submiss
manta/manta-ray reach certain enrol threshold similarli unlik assum
fda hold firm decis manta/manta-ray complet prior nda submiss
use result comp analysi determin like delay durat
thu assign follow probabl delay scenario base comp analysi
base analysi approv drug evid testicular toxic assign
follow probabl regard final readout manta/manta-ray
tabl probabl distribut scenario outcom
result probabl distribut potenti scenario tabl probabl
distribut overlaid respect price target creat heat map shown tabl
heat map highlight like price target rang per share
equat reduct prior price target per share
use price probabl distribut across scenario determin probabl
weight averag price per share shown tabl
tabl heat map price target base probabl scenario outcom show
like price target rang per share
tabl probabl weight averag price per share
time money manta-ray show worth ask question much time
npv save addit manta-ray studi use enrol rate determin
comp analysi determin manta would reach enrol
threshold april march use timelin assumpt comp
analysi would project launch window year delay
versu origin launch date filgotinib amount month
month time save addit manta-ray compar estim cost
initi run manta-ray valuat model determin time
save trial equat npv
manta/manta-ray outcom impact pt
base probabl distribut
base probabl weight averag price
ra urgent need new therapi believ fda hold firm decis see result
manta/manta-ray prior filgotinib nda file
scenario analysi base histor recruit rate assum variabl toxic find see month project
launch delay versu prior estim
impact delay galapago target price lower previou pt rang assum mild
testicular toxic signal observ manta/manta-ray
new pt base probabl weight averag price across model scenario
manta manta-ray creat risk glpg price
pend fda discuss determin fate
manta/manta-ray path time
nda file filgotinib
posit top-lin result hand three
phase finch trial filgotinib rheumatoid arthriti
ra glpg partner plan enter talk
fda discuss fda prior request
testicular toxic safeti studi complet ahead
nda file filgotinib
address request glpg initi
phase manta trial juli studi effect
filgotinib testicular activ ulcer coliti uc
patient howev trial slower
anticip enrol lead expans
inclus criteria includ patient
inflammatori bowel diseas initi
phase manta-ray expand enrol
patient rheumat diseas
manta manta-ray patient combin
final testicular toxic analysi
expect fda revers prior request
due high avail treatment ra
rais threshold drug seek approv
potenti delay creat risk rel
month price target glpg compound
potenti testicular toxic signal could appear
trial
assum time complet
file therefor outcom
manta/manta-ray price
target glpg unknown
know long
manta/manta-ray delay launch
filgotinib due lack transpar
trial
testicular toxic signal would neg
need understand impact possibl
outcom trial
price target glpg
bound uncertainti around manta/manta-ray impact
perform comp analysi project time rang complet manta/manta-ray launch date filgotinib combin
scenario analysi determin impact manta/manta-ray price target
compar clinic trial use separ estim
enrol rate manta manta-ray base
number studi site-month enrol activ
site activ compar trial obtain
histor archiv clinicaltri gov
scenario analysi map price target rang
construct scenario analysi map potenti price
target impact caus delay launch testicular
toxic signal manta/manta-ray
delay launch filgotinib model year
increment begin delay extend
rate use estim current number
patient enrol follow extrapol rate
estim time rang complet manta/manta-ray
asset profil distribut increment shift
toward undifferenti profil model impact
result manta/manta-ray
assum manta-ray activ trial site
averag per month site
even though patient need top-lin
analysi project total enrol patient
ensur patient reach primari endpoint
rate estim
number cumul patient
time complet
data clean present
month
nda prepar file
month
fda decis prioriti review
manta manta-ray trial design
measur filgotinib impact sperm count
patient ulcer coliti crohn diseas
patient diagnos activ rheumatoid arthriti psoriat
patient receiv mg filgotinib placebo daili
week
patient experi decreas sperm
concentr option enter
ibd clinic respond remain blind studi treatment
ibd clinic non-respond receiv open-label filgotinib
arthriti ankylos spondyl non-radiograph axial
patient receiv mg filgotinib placebo daili
patient experi decreas sperm
concentr arthriti non-respond week
receiv local standard care monitor week
patient experienc decreas sperm concentr
week receiv standard care monitor
week semen paramet revers
number need read enrol patient combin manta manta-ray deliv result patient total
final assess
proport particip decreas baselin sperm concentr week
secondari endpoint evalu week
proport particip decreas baselin sperm concentr week
chang baselin
total sperm count week
clinicaltri gov svb leerink research
comp analysi project year delay filgotinib launch
analysi indic total delay month year versu current project launch date
phase trial upadacitib crohn diseas cd phase trial mirikizumab ulcer coliti uc
use estim low high enrol rate respect manta
high enrol rate manta-ray determin use phase trial filgotinib ra
phase trial upadacitinib ra respect
activ site project linear growth total patient enrol manta addit site project activ
manta-ray project exponenti growth total patient enrol new trial site activ ramp total enrol rate
estim patient enrol manta/manta-ray date
enrol project patient ensur patient evalu
project simul timelin market launch filgotinib
enrol
file nda
filgotinib ra
top-line result
regulatori decis
filgotinib launch
ra uc
glpg meet fda
discuss nda file
top-line result
top-line result
regulatori decis
filgotinib launch
ra uc
enrol
file nda
filgotinib ra
scenario analysi price target
impact manta/manta-ray outcom
probabl distribut
probabl distribut
scenario analysi price target distribut
likelihood manta/manta-ray outcom
base comp analysi
price target per share determin
per share
month month delay minim toxic
signal determin mostli like base
probabl distribut inform comp analysi
time money manta-ray gain year npv
manta timelin
manta
timelin manta-ray
manta
manta-ray reduc potenti delay launch month year
translat npv gain launch manta-ray
good sold
research develop expens
gener administr expens
sale market expens
profit loss oper
fair valu re-measur share subscript agreement
total incom expens
loss oper tax
good sold
research develop expens
gener administr expens
sale market expens
profit loss oper
fair valu re-measur share subscript agreement
total incom expens
loss oper tax
growth profit ratio
cash equival
trade receiv
properti plant equip
trade payabl
share premium account addit paid capit
total liabil stockhold equiti deficit
outstand share end period thousand
select metric thousand except per share
work capit thousand
cash equival market secur
cash equival
trade receiv
properti plant equip
trade payabl
total liabil stockhold equiti deficit
outstand share end period thousand
select metric thousand except per share
work capit thousand
cash equival market secur
flow oper activ
reconcili net loss net cash
adjust non-cash transact
adjust item disclos separ oper cash flow
adjust item disclos invest financ cash flow
increas decreas oper asset liabil
chang work capit defer incom
decreas defer incom
oper activ work capit cash flow
net interest tax- oper cash flow
net cash use oper activ
flow invest activ
purchas properti plant equip
purchas expenditur intang fix asset
proce dispos properti plant equip
decreas restrict cash
proce sale financi asset held fair valu profit loss
acquisit available-for-sal financi asset
net cash provid use invest activ
flow financ activ
repay oblig financ leas debt
proce capit share premium increas gross amount
issu cost paid relat capit share premium increas
proce capit share premium increas exercis warrant
net cash provid financ activ
effect exchang rate differ cash cash equival
net increas decreas cash cash equival
 cash equiv begin period
 cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
flow oper activ
reconcili net loss net cash
adjust non-cash transact
adjust item disclos separ oper cash flow
adjust item disclos invest financ cash flow
increas decreas oper asset liabil
chang work capit defer incom
decreas defer incom
oper activ work capit cash flow
net interest tax- oper cash flow
net cash use oper activ
flow invest activ
purchas properti plant equip
purchas expenditur intang fix asset
proce dispos properti plant equip
decreas restrict cash
proce sale financi asset held fair valu profit loss
acquisit available-for-sal financi asset
net cash provid use invest activ
flow financ activ
repay oblig financ leas debt
proce capit share premium increas gross amount
issu cost paid relat capit share premium increas
proce capit share premium increas exercis warrant
net cash provid financ activ
effect exchang rate differ cash cash equival
net increas decreas cash cash equival
 cash equiv begin period
 cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
